A once-weekly injectable suspension has been approved in the U.S. for the treatment of type 2 diabetes. Marketed by AstraZeneca as BYDUREON BCise (exenatide extended-release), it has been shown to to improve glycemic control in pediatric patients (10 to 17 years) as an adjunct to diet and exercise. The approval by the US Food and...
Author: Mark Newman
Cushing’s disease continues to confound endocrine clinicians due to the manner in which it mimics more commonplace disorders. We talk to Anthony Heaney, MD, PhD, about his CEU 2021 session, “Challenges in the Management of Cushing’s Disease” and what attendees can expect to learn about this rare endocrine condition. Cushing’s disease is a rare disorder... As pediatric diabetes cases continue to rise, a number of manufacturers have created products that make managing the disease a little less scary for these younger patients. Pediatric diabetes is on the rise. While type 1 diabetes can develop at any age, it is most prevalent in children and teens – the average age of...
As you read this issue in the middle of summer, there is certainly no sign of any of the typical summer doldrums and that is largely due to the amazing events the Endocrine Society is known for around the world. Not only does the July issue feature research presented at the first-ever all virtual ENDO...Antidepressants May Improve Outcomes in People with Diabetes and Depression
People with diabetes and depression who take antidepressants may have a lower risk of death and of serious diabetes complications, according to a new study published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism. People with diabetes face a higher risk of depression, which makes them more likely to die or develop diabetes complications...
Teamwork is often vital to improving patient outcomes. And while most healthcare professionals are in favor of working together, the biggest obstacle appears to be simply finding the time to team up. In a survey conducted last summer by the market research and analytics company The Harris Poll for Boehringer Ingelheim and Eli Lilly and...
Immerse Yourself in the Latest Advances at Our Fall Meetings
We are thrilled to deliver the most up-to-date educational content during our Clinical Endocrinology Update (CEU) and Endocrine Board Review (EBR) meetings this fall. A record number of attendees joined us last year for the first-ever virtual CEU and EBR events, with more than 1,100 participants attending CEU 2020 and more than 600 taking part...Kids in Lockdown: How COVID-19 Affected Children with Type 1 Diabetes
ENDO 2021 presented a plethora of research detailing how COVID-19 impacted a number of endocrine comorbidities. However, two studies in particular took a closer look at how the virus impacted pediatric patients with type 1 diabetes. Each year, ENDO is something of an “embarrassment of riches” because it consists of four days packed with the...
